The Latest Breaking News from Oncology

Much-loved matriarch Faith Dingle, played by Sally Dexter, will attend an oncology appointment after having her scan - but it's not good news on Emmerdale

invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ:FSTX) for $7.12 per share.  The proposed acquisition values F-star at approximately $161 million.  Just a year ago, F-star priced its IPO at $7. F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global…

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

Clovis Oncology Inc (NASDAQ:CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).  Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in…

MorphoSys AG (NASDAQ:MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio is a biotechnology company based in South San Francisco that focuses on discovering and…

Leader Stephen Cullen was inspired by his experience at the Children’s Haematology and Oncology Unit at the Royal

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab.  Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy.  The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

The findings — presented at the American Society of Clinical Oncology meeting in Chicago — could allow doctors to “focus on the patients we think would truly benefit from chemotherapy and avoid the side effects for patients for whom it’s likely unnecessary,” one expert said.

Verastem Oncology (NASDAQ:VSTM) brought in sales totaling $2.60 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.92%, resulting in a loss of $16.96 million.